56. Behcet disease
[
41 clinical trials,
63 drugs（DrugBank:
22 drugs),
33 target genes / 101 target pathways ]
Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900027147 | 2020-01-01 | 4 November 2019 | Efficacy and safety of adalimumab in Behcet's disease-related uveitis | Efficacy and safety of adalimumab in Behcet's disease-related uveitis | Behcet's disease-related uveitis | 1:Adalimumab; | State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University | Not Recruiting | Both | 1:30; | Phase 4 | China | |||
| 2 | NCT04065672 | October 15, 2019 | 28 October 2019 | Low-dose IL-2 Treatment on Behcet's Disease | Low-dose IL-2 Treatment on Behcet's Disease | Behcet's Disease | Drug: Low-dose IL-2 | Peking University People's Hospital | Not recruiting | 18 Years | 70 Years | All | 15 | Phase 2 | China | |
| 3 | NCT03771768 | May 25, 2019 | 23 April 2019 | Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease | Active Control,Randomized,Double- Blinded Clinical Trial of BD | Autoimmune;Behcet Syndrome | Radiation: Diode laser 980nm&100 mWatt;Drug: Triamcinolone Acetonide | Cairo University | Not recruiting | 18 Years | 60 Years | All | 38 | N/A | ||
| 4 | NCT03888846 | March 25, 2019 | 26 August 2019 | Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers | Clinical Protocol for Administration of Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers | Behçet Disease Affecting Oral Mucosa | Drug: Pentoxifylline;Drug: Colchicine | Ipekyolu Ilac Ltd. Sti | Istanbul University-Cerrahpasa School of Medicine | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | Turkey |
| 5 | NCT04022421 | October 1, 2018 | 29 July 2019 | Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis | The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention | Behcet's Syndrome, Vascular Type | Drug: Hydroxychloroquine | Assiut University | Recruiting | 18 Years | N/A | All | 50 | N/A | Egypt | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03522662 | August 1, 2018 | 11 June 2018 | Anti IL-18 (GSK1070806) in Behcet's Disease | An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease | Behcet's Disease | Drug: GSK1070806 | Cambridge University Hospitals NHS Foundation Trust | Not recruiting | 18 Years | N/A | All | 12 | Phase 2 | United Kingdom | |
| 7 | NCT03371095 | March 15, 2018 | 12 March 2018 | Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet Disease | Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet Disease | Behcet's Disease;Vasculitis | Drug: Infliximab;Drug: Cyclophosphamide | Assistance Publique - Hôpitaux de Paris | Not recruiting | 12 Years | N/A | All | 52 | Phase 3 | ||
| 8 | NCT03274648 | October 2017 | 16 December 2017 | Dietary Interventions and Butyrate Production in Behçet's Patients | Therapeutic Modulation of Butyrate Production in Behçet's Patients: a Dietary Intervention Trial | BehçEt Disease | Dietary Supplement: Oral butyrate;Dietary Supplement: Vegetarian diet;Dietary Supplement: Habitual diet | Azienda Ospedaliero-Universitaria Careggi | Not recruiting | 18 Years | 70 Years | All | 30 | N/A | ||
| 9 | NCT03209219 | June 30, 2017 | 2 July 2018 | Interferon a2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis | Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet`s Disease Uveitis | Behçet Disease;Uveitis | Drug: Cyclosporine Pill;Drug: Interferon Alfa-2A | gwcmc | Recruiting | 18 Years | 65 Years | All | 36 | Phase 3 | China | |
| 10 | NCT02648581 | June 14, 2017 | 30 September 2019 | Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease | A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease | Behçet Disease | Drug: Subcutaneous Ustekinumab | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | All | 16 | Phase 2 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | JPRN-UMIN000025451 | 2017/04/01 | 22 July 2019 | Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease | Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease | refractory uveitis of Behcet's disease | Patients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year. | Yokohama City University Hospital | Not Recruiting | 20years-old | 65years-old | Male and Female | 5 | Not selected | Japan | |
| 12 | EUCTR2017-002264-41-FR | 28 February 2019 | NA | Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Infliximab to that of Cyclophosphamide in severe Behçet's disease - ITAC | Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease MedDRA version: 20.0 Level: LLT Classification code 10004212 Term: Behcet's disease System Organ Class: 100000017240 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Remicade 100 mg Product Name: Remicade 100 mg Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: infliximab Other descriptive name: infliximab Trade Name: cyclophosphamide Product Name: cyclophosphamide Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: cyclophosphamide Other descriptive name: cyclophosphamide | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Not Available | Female: yes Male: yes | 52 | Phase 2 | France | ||||
| 13 | NCT02756650 | June 23, 2016 | 4 March 2019 | 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement | An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement | Behcet Disease | Drug: drug administration | Novartis Pharmaceuticals | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | Turkey | |
| 14 | JPRN-UMIN000020029 | 2016/04/01 | 22 July 2019 | The significance of serum HBs-antigen as a monitoring examination for viral reactivation during immunesuppressive therapy in patients with previously resolved hepatitis B virus infection | The significance of serum HBs-antigen as a monitoring examination for viral reactivation during immunesuppressive therapy in patients with previously resolved hepatitis B virus infection - Monitoring by HBs antigen for HBV Reactivation | Collagen disease, collagen disease related disease, ulcerative colitis, Crohn's disease, intestinal Behcet's disease (simple ulcers included), psoriasis, and diseases that require other immunosuppressive therapies. | Entecavir administration is initiated when serum HBV-DNA levels increased up to 3.0 Log/IU/mL and/or serum HBs-antigen becomes detectable. | Saitama Medical University | Recruiting | 16years-old | Not applicable | Male and Female | 300 | Not selected | Japan | |
| 15 | EUCTR2014-005390-36-GB | 17/02/2016 | 30 May 2016 | BIO BEHCET'S TRIAL | Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment. - BIO BEHÇET’S | Behcets Disease MedDRA version: 18.1 Level: LLT Classification code 10004212 Term: Behcet's disease System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Remicade Product Name: Remicade Product Code: 3400935113276 Pharmaceutical Form: Powder for infusion INN or Proposed INN: infliximab CAS Number: 170277-31-3 Current Sponsor code: PF-06438179 Concentration unit: g gram(s) Concentration type: up to Concentration number: 5- Trade Name: Roferon-A, 3miu Product Name: Roferon-A 3miu Product Code: 8699505952864 Pharmaceutical Form: Solution for injection INN or Proposed INN: alpha interferon CAS Number: 9008-11-1 Concentration unit: million IU million international units Concentration type: equal Concentration number: 3- Trade Name: Roferon-A, 4.5miu Product Name: Roferon-A, 4.5miu Product Code: J1081 Pharmaceutical Form: Suspension for injection INN or Proposed INN: alpha interferon Concentration unit: million IU million international units Concentration type: equal Concentration number: 4.5- Trade Name: Roferon-A, 6miu Product Name: Roferon-A, 6miu Product Code: 2387066 Pharmaceutical Form: Solution for injection INN or Proposed INN: alpha interferon Concentration unit: million IU million international units | The University of Liverpool | Authorised | Female: yes Male: yes | 100 | Phase 3 | United Kingdom | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02505568 | July 22, 2015 | 28 October 2019 | A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease | An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease | Behcet Disease | Drug: Infliximab | Janssen Korea, Ltd., Korea | Not recruiting | 19 Years | 75 Years | All | 33 | Phase 3 | Korea, Republic of | |
| 17 | EUCTR2014-002108-25-DE | 17/06/2015 | 11 April 2016 | Study to test whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment of active Behçet’s disease (oral ulcers). This study also tests how well the body tolerates apremilast. The study is conducted in several centers in different countries. | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF SUBJECTS WITH ACTIVE BEHÇET’S DISEASE | SUBJECTS WITH ACTIVE BEHÇET’S DISEASE MedDRA version: 18.1 Level: LLT Classification code 10004212 Term: Behcet's disease System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Apremilast Product Code: CC-10004 Pharmaceutical Form: Tablet INN or Proposed INN: APREMILAST CAS Number: 608141-41-9 Current Sponsor code: CC-10004 Other descriptive name: APREMILAST Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Apremilast Product Code: CC-10004 Pharmaceutical Form: Tablet INN or Proposed INN: APREMILAST CAS Number: 608141-41-9 Current Sponsor code: CC-10004 Other descriptive name: APREMILAST Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Apremilast Product Code: CC-10004 Pharmaceutical Form: Tablet INN or Proposed INN: APREMILAST CAS Number: 608141-41-9 Current Sponsor code: CC-10004 Other descriptive name: APREMILAST Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Celgene Corporation | Authorised | Female: yes Male: yes | 204 | Phase 3 | France;United States;Turkey;Israel;Germany;Japan;Italy;Korea, Republic of | |||
| 18 | NCT02258867 | November 2014 | 18 January 2016 | Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis | A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis | Behcet's Disease Uveitis | Drug: Placebo;Drug: Gevokizumab | XOMA (US) LLC | Not recruiting | 18 Years | N/A | Both | 4 | Phase 3 | United States | |
| 19 | NCT01988506 | January 6, 2014 | 27 August 2018 | Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases | Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach | Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis | Drug: Interleukin 2 | Assistance Publique - Hôpitaux de Paris | Iltoo Pharma | Recruiting | 18 Years | N/A | All | 132 | Phase 2 | France |
| 20 | JPRN-UMIN000012469 | 2013/12/02 | 7 October 2019 | Comparison of Adalimumab and Steroid in Intestinal Behcet's disease | Comparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study | Intestinal Behcet's disease | Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously. Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately | Castle Study Group | Recruiting | 15years-old | Not applicable | Male and Female | 50 | Not selected | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02620618 | January 2013 | 14 December 2015 | Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study | Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study | Behçet's Disease;Uveitis | Drug: Intravitreal Infliximab | Cairo University | Not recruiting | N/A | N/A | Both | 20 | Phase 1/Phase 2 | ||
| 22 | NCT01965145 | November 2012 | 11 June 2018 | Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) | A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis | Behcet's Uveitis | Drug: Gevokizumab;Drug: Placebo | Servier | Not recruiting | 18 Years | N/A | All | 84 | Phase 3 | Korea, Republic of;United Kingdom | |
| 23 | EUCTR2012-001125-27-DE | 24/09/2012 | 12 October 2015 | Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis | A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis EYEGUARD TM -B | Behçet’s disease uveitis MedDRA version: 17.1 Level: LLT Classification code 10071139 Term: Behcet's uveitis System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Gevokizumab Product Code: S78989 Pharmaceutical Form: Solution for injection INN or Proposed INN: gevokizumab CAS Number: 1129435-60-4 Current Sponsor code: S78989 Other descriptive name: XOMA 052 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Institut de Recherches Internationales Servier | Not Recruiting | Female: yes Male: yes | 44 | Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Germany;Tunisia;China;Korea, Republic of | ||||
| 24 | NCT01532570 | January 2012 | 19 October 2017 | Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions | To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650 | Behcet's Disease;Behcet Syndrome;Neuro-Behcet's Disease | Drug: TA-650 | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 16 Years | 75 Years | All | 18 | Phase 3 | Japan | |
| 25 | EUCTR2010-024152-29-DE | 02/09/2011 | 19 March 2012 | An open-label study to evaluate efficacy and tolerability of Canakinumab in patients with Behçet Disease who do not respond to standard treatment (Eine offene Studie zur Wirksamkeit und Verträglichkeit von Canakinumab bei Patienten mit Morbus Behçet, die auf die übliche Behandlung nicht ansprechen) | Canakinumab for Behçet`s Disease Resistant to Standard Treatment (CanBeDisT) - CanBeDisT | Behçet`s Disease MedDRA version: 14.0 Level: PT Classification code 10004213 Term: Behcet's syndrome System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Ilaris Product Name: Ilaris Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CANAKINUMAB CAS Number: 914613-48-2 | University Hospital of Tübingen | Authorised | Female: yes Male: yes | 10 | Germany | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT01441076 | September 2011 | 16 December 2017 | Anakinra for Behcet s Disease | A Pilot Study of Anakinra in Behcet's Disease (BD) | Autoimmune Connective Tissue Disorder;Immune System Diseases | Drug: Anakinra | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Not recruiting | 18 Years | 65 Years | All | 6 | Phase 1/Phase 2 | United States | |
| 27 | NCT00931957 | October 2010 | 19 February 2015 | Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease | Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease | Behcet Syndrome;Uveal Disease | Drug: Etanercept, Methotrexate, Prednisolone | Tehran University of Medical Sciences | Wyeth is now a wholly owned subsidiary of Pfizer | Recruiting | 16 Years | 60 Years | Both | 80 | N/A | Iran, Islamic Republic of |
| 28 | NCT01243671 | October 2010 | 19 October 2017 | A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease | A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease | Intestinal Behçet's Disease | Biological: Adalimumab | AbbVie (prior sponsor, Abbott) | Eisai Co., Ltd. | Not recruiting | 15 Years | N/A | All | 20 | Phase 3 | Japan |
| 29 | NCT01211977 | August 27, 2010 | 16 December 2017 | A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease | A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD) | Muckle Wells Syndrome;Autoinflammatory;Behcet's Disease | Drug: XOMA 052 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Not recruiting | 18 Years | N/A | All | 0 | Phase 1/Phase 2 | United States | |
| 30 | NCT01306955 | February 2010 | 19 February 2015 | The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease | The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study | Behcet's Disease | Drug: methylorednisolone;Other: dextrose water 5% | Tehran University of Medical Sciences | Recruiting | 10 Years | 70 Years | Both | 34 | Phase 4 | Iran, Islamic Republic of | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2009-013901-33-AT | 12/11/2009 | 19 March 2012 | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0 Level: LLT Classification code 10036370 Term: Posterior uveitis | Product Name: AIN457 Product Code: AIN457 Pharmaceutical Form: Powder for solution for infusion Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Subcutaneous use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 112 | Germany;France;Spain;Greece;Austria | ||||
| 32 | EUCTR2009-011237-27-HU | 15/10/2009 | 2 March 2015 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0 Level: LLT Classification code 10036370 Term: Posterior uveitis | Product Name: AIN457 Product Code: AIN457 Pharmaceutical Form: Powder for solution for injection Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use | Novartis Pharma Services Ag | Not Recruiting | Female: yes Male: yes | 112 | France;Hungary;Greece;Spain;Austria;Germany;Italy | ||||
| 33 | NCT00866359 | August 1, 2009 | 16 December 2017 | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease | Behcet Syndrome | Drug: Apremilast (CC-10004);Drug: Placebo | Celgene | Not recruiting | 18 Years | N/A | All | 111 | Phase 2 | United States;Turkey | |
| 34 | NCT00720928 | July 2008 | 19 February 2015 | Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease | A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease | Ocular Behcet's Disease,;Non-Infectious Uveitis;Refractory Uveitis | Drug: flucinolone acetonide | Asan Medical Center | Samsung Medical Center;Seoul National University Hospital;Kyunghee University Medical Center | Recruiting | 18 Years | N/A | Both | 15 | Phase 4 | Korea, Republic of |
| 35 | NCT00550498 | December 2007 | 23 November 2015 | Stem Cell Transplantation in Ocular Lesions of Behcet's Disease | Phase 1 Study of Bone Marrow - Derived Stem Cell in the Treatment of Ocular Lesions of Behcet's Disease | Retinitis;Behcet's Syndrome | Biological: Autologous Stem Cell Transplantation | Tehran University of Medical Sciences | Not recruiting | 16 Years | N/A | Both | 5 | Phase 1 | Iran, Islamic Republic of | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT00483184 | April 2006 | 19 October 2017 | Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease | Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease | Behcet Syndrome;Behcet Disease;Mucocutaneous Ulceration | Biological: Veldona, | Nobel Pharmaceuticals | Amarillo Biosciences, Inc. | Not recruiting | 18 Years | 75 Years | All | 84 | Phase 2 | Turkey |
| 37 | NCT00664599 | April 2006 | 19 February 2015 | Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease | Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study) | Behcet's Syndrome | Drug: Rituximab;Drug: Cytotoxic Combination | Tehran University of Medical Sciences | Hoffmann-La Roche | Not recruiting | 16 Years | N/A | Both | 20 | Phase 2 | Iran, Islamic Republic of |
| 38 | NCT00167583 | November 2004 | 11 June 2018 | Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) | Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) | Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal Vasculitis | Drug: Cyclosporin A;Drug: Interferon-alpha2a | University Hospital Tuebingen | Not recruiting | 18 Years | 75 Years | All | 37 | Phase 3 | Germany | |
| 39 | NCT00278512 | August 2003 | 8 August 2016 | Hematopoietic Stem Cell Support in Vasculitis | High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome | Vasculitis | Biological: Autologous Stem Cell Transplant;Biological: Allogeneic Stem Cell Transplant | Northwestern University | Not recruiting | 16 Years | 60 Years | Both | 7 | Phase 1 | United States | |
| 40 | NCT00700297 | August 2002 | 19 February 2015 | Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease | A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet`s Disease | Behcet's Syndrome | Drug: Colchicine;Drug: Placebo | Tehran University of Medical Sciences | Not recruiting | 14 Years | 60 Years | Both | 169 | Phase 2 | Iran, Islamic Republic of | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT00001865 | July 1999 | 19 February 2015 | HAT in Eye Complications of Behcet's Disease | A Study to Investigate the Safety and Efficacy of HAT to Treat the Ocular Complications Related to Behcet's Disease | Behcet's Syndrome;Retinal Disease;Uveitis | Drug: Daclizumab | National Eye Institute (NEI) | Not recruiting | N/A | N/A | Both | 26 | Phase 2 | United States |